We are approaching the ten-year mark for the Quality by Design initiative in the pharmaceutical industry. Much has been accomplished and demonstrated, particularly with regard to enhanced understanding of processes and better definition of processing parameters such as CPPs. Design space has become an often utilized term when process scientists talk about their projects and the concept has led to increased use of modeling approaches in late stage development. Despite the interest generated by the initiative and the progress made by it's participants, the true power of QbD may yet to be unleashed. Human-centered design of pharmaceuticals, with a more intimate tie to patient need and patient performance, should be the next step in how we more forward the QbD initiative, and represents a new way for engineers to influence drug design.
Would you like to access this content?
No problem. You just have to complete the following steps.
You have completed 0 of 2 steps.
You must be logged in to view this content. Log in now.
Purchase Technical Presentation
You must purchase this technical presentation using one of the options below.
If you already purchased this content recently, please click here to refresh the system's record of ownerships.
|Credits||0.5 Use credits|
|List Price||$25.00 Buy now|
|AIChE Members||$15.00 Buy now|
|AIChE Undergraduate Student Members||Free Free access|
|AIChE Graduate Student Members||Free Free access|